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 A b s t r a c t  
Ion exchange resins are commonly used for masking of drug objectionable taste. Our work aimed to 
study the effect of this complexation on the drug stability and bioavailability in rabbits. In this work, 
paracetamol and ibuprofen complexes with indion 204 were prepared; drug stability and 
bioavailability from the prepared complexes were studied and compared with that of the commonly 
used commercial tablets Tylenol and Motrin respectively. The clinical protocol and information about 
drugs were discussed with a group of healthy albino rabbits. The results showed that tmax of both 
drugs were kept constant at 1.5hrs and 2hrs without any change from the reference standards 
Tylenol and Motrin respectively. The calculated pharmacokinetic parameters Cpmax, AUC(0-24) and 
AUC(0-∞) respectively for paracetamol were 0.431µg/ml, 3.535µg.hr/ml and 3.756µg.hr/ml from the 
prepared complexes in comparison to 0.494µg/ml, 4.083µg.hr/ml, 4.198µg.hr/ml from Tylenol, and 
0.743µg/ml, 5.380µg.hr/ml, 5.559µg.hr/ml from the prepared ibuprofen complexes in comparison to 
0.803µg/ml, 6.272 µg.hr/ml, 6.432 µg.hr/ml from Motrin. The relative bioavailability of both drugs 
from the prepared complexes were calculated using Tylenol and Motrin as reference standards and 
the 90 % confidence intervals of the geometric mean values for the test/reference ratios for Cpmax, 
AUC (0-24) and AUC (0-∞) were within the bioequivalence acceptance range of 80–125 % according to 
the European Guideline. Statistical analysis (ANOVA) indicated a significance difference between 
the calculated pharmacokinetic parameters for both drugs. From these results we can conclude that 
indion complexation of drugs significantly affects their pharmacokinetics and retards their 
bioavailability. 
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Introduction 
E. coli K88 is a major pathogen that infects newborn and weaned 
piglets. This problem leads to great economic losses for the pork 
industry[1]. E. coli K88 is a Gram negative bacillus that expresses 
an adhesin-type lectin with specificity toward glycoproteins present 
in the intestine of piglets [2]. Additionally, this bacteria is toxin-
producing and enterotoxigenic, triggering intestinal osmotic 
imbalance and severe diarrhea in susceptible animals[3]. Although 
there have been several studies aimed at the prevention of 
bacterial infection, when disease is established, the solution is 
antibiotic therapy. 
The use of antimicrobials in animals raised for human consumption 
is controversial due to the constant increase in multidrug pathogen 
resistance to antibiotics [4]. Inadequate practices, such as the use 
of subtherapeutic antibiotic doses to promote animal growth or the 
use of high therapeutic doses, lead to increased bacterial 
resistance. Because antibiotics are the main tools for fighting 
infections, necessary measures for safe use should be taken. 
When farm animals have an infection, the parenteral route is the 
most commonly used route of administration for antibiotics. The 
concentrations obtained by intramuscular or intravenous routes of 
administration are much higher than an equivalent dose of a drug 
given orally [5]. However, intramuscular or intravenous routes of 
administration inevitably lead to systemic distribution of antibiotics, 
possible toxicity and accumulation in tissue [6- 7]. Several studies 
agree that the localized administration of antimicrobials may lead to 
dose reduction and elimination of adverse side effects [7- 8]. 
For gastrointestinal infections, the administration of poorly 
absorbable antibiotics (such as vancomycin, neomycin, colistin, 
nystatin and gentamicin) is an alternative treatment to produce 
localized activity and to reduce systemic toxicity [8].  
Gentamicin is widely used to treat infections caused by E. coli K88 
in pig farms [9]. In the last decade, gentamicin has been reported 
to cause less resistance than other antibiotics, including 
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spectinomycin, tetracycline, ampicillin, carbenicillin, neomycin and 
sulfamethoxazole [9]. Additionally, gentamicin is approved by the 
FDA for use in animals raised for human consumption[10]. For this 
reason, the efficient use of gentamicin is needed for E. coli K88 
treatment.Oral administration of gentamicin is not effective, 
although it shows sensitivity in vitro [11]. The lack of activity in vivo 
could be related to poor distribution in the intestinal mucosa, which 
reduces both contact with and elimination of pathogens [12]. The 
rapid excretion of gentamicin though feces could also explain its 
low oral therapeutic effect. 
An alternative delivery approach that may be useful for the 
distribution and maintenance of gentamicin in the gastrointestinal 
tract is the use of microspheres. Microspheres are transport 
systems based on solid polymers that allow for an effective control 
of drug release. In this regard, the controlled drug delivery systems 
have many benefits, for example, improved therapy by increasing 
efficacy and gastrointestinal transit time, convenient routes of oral 
administration and enhanced site-specific delivery to reduce 
unwanted adverse effects[13]. 
It has been shown that microparticles greater than or equal to 5 µm 
can contact and stay in the intestinal mucosa up to 24 h before 
elimination [14]. This behavior may allow the release and 
distribution of active substances in the intestinal space. 
In recent years, more than 100 biologically active compounds have 
been incorporated into albumin microspheres for many treatment 
applications [15]. Here, albumin microspheres were synthesized to 
encapsulate gentamicin. In vitro release of gentamicin was 
evaluated, and susceptibility tests with E. coli K88 were performed 
using encapsulated antibiotics in albumin microspheres. 
Materials and Methods 
Materials 
Bovine serum albumin (BSA) fraction V, gentamicin sulfate, 
glutaraldehyde (25 wt %) and Span® 80 were purchased from 
Sigma-Aldrich, St Louis, Mo. USA. Culture medium was purchased 
from BD Difco™, MD, USA. Other chemicals used were analytical 
grade.  
Preparation of microspheres 
Gentamicin-albumin microspheres (GAM) were prepared according 
to the method proposed by Mathew et al. [16] and modified as 
follows. One milliliter of an aqueous solution with 20% BSA and 
0.4% gentamicin sulfate was added to 30 mL of mineral oil 
containing 0.1% (wt/wt) Span 80® and stirred at 2000 rpm. After 1 h 
of continuous stirring (to obtain a homogeneous emulsion), 4.2, 8.2 
and 16.8 mg/g of toluene-saturated glutaraldehyde were added to 
cross-link the G1, G2 and G3 microsphere formulations, 
respectively. Stirring continued for an additional 4 h, and then the 
microspheres obtained were recovered by centrifugation (5 min at 
300 g). Finally, the microspheres were washed three times with 
hexane and dried at room temperature.  
Particle size distribution and morphology 
GAM particle size and distribution was measured using a Coulter 
Multisizer 3 (Beckman Coulter). Phosphate buffered saline (PBS) 
was used as a dispersing medium. Morphology was examined with 
scanning electron microscopy (SEM) using a Hitachi S-4800 Type 
II Ultra-High SEM. Samples were coated with conductive 
gold/palladium (60/40) prior to scanning at 5.0 kV [16]. 
Yield, encapsulation efficiency and release efficiency of 
microspheres 
The obtained microspheres were weighed to determine yield using 
the following formula [17]:  
 
Yield(%)=weight of microspheres obtained X 100 / weight of BSA+ 
weight of gentamicin 
  
The encapsulation efficiency was determined by Fourier Transform 
Infrared (FT-IR) spectra according to Matkovic et al. [18] and 
Bunaciu et al. [19]. A Nicolet Protégé (System 460 E.S.P.) FT-IR 
spectrometer (Madison WI, USA) was used at a resolution of 0.5 
cm-1. Scanning was performed in the 4000-600 cm-1 wavelength 
range. Quantitative analysis of gentamicin in the microspheres was 
performed with the FT-IR spectra of albumin:gentamicin (1:1, 2.5:1, 
5:1 and 10:1). Samples were well mixed with potassium bromide 
(KBr), and KBr acted as an infrared-transparent matrix. Disks 
containing the mixture of albumin:gentamicin and KBr were 
compacted using a hydraulic press. Calibration curves were 
obtained by plotting the area under the peak at 1100-1400 cm-1 vs. 
the concentration of gentamicin in the matrix. Encapsulation 
efficiency was obtained using the formula:  
 
Ee%=amount of gentamicin found in microspheres x 100 / amount 
of gentamicin 
  
Release efficiency was determined using a dialysis system [20]. 
Fifty milligrams of GAM dispersed in 5 ml of PBS (pH 7.2) was 
placed in a dialysis bag and incubated in 30 ml of the same buffer 
solution. The flask was subjected to sonication for 2 h. 
Subsequently, the microsphere suspension was placed in a 
shaking apparatus for three days. The gentamicin concentration in 
the external phase was quantified photometrically at 320 nm after 
derivatization with O-phthaldehyde [21]. The derivatizing agent was 
prepared according to Fayle et al. [22]. Sixty milligrams of O-
phthaldehyde were solubilized in 30 ml of 0.1 M sodium borate with 
200 µl of 2-mercaptoethanol and 20 ml of distilled water. 
In vitro release studies 
Twenty milligrams of GAM dispersed in 2 ml of PBS (pH 7.2) was 
placed in a dialysis bag and incubated in 20 ml of the same buffer 
solution. Similarly, the kinetics of release were evaluated in 
glycine-HCl buffer (pH 2), acetate buffer (pH 4) and PBS (pH 6). 
Dialysis studies were carried out at 37°C with continuous agitation. 
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At specific time intervals, 2 ml of external phase was taken to 
quantify the released gentamicin using a derivatizing agent (as 
described previously). Two milliliters of buffer was added to the 
external phase to compensate for the volume removed for analysis. 
In vitro release testing was repeated using GAM treated with 
trypsin and chymotrypsin under the different conditions. Solutions 
were adjusted to 55 U for trypsin and 9.5 U for chymotrypsin in 
PBS (pH 7.4) according to Jensen et al. [23]. 
The release behavior of gentamicin from albumin microspheres 
was analyzed by a mass balance in the sphere, generating the first 
order equation:  
 
Dc / dt = -kbc 
  
where kb is the initial burst constant. Because the initial 
concentration in the particle is equal to the initial mass of drug 
loaded into microparticles per volume of microparticles, the solution 
becomes: 
 
mt / m =1 – e-kbt 
 
where mt is the cumulative amount of drug released at time t, m∞ is 
the initial amount of drug loaded in the microparticle, and mt/m∞ is 
the fraction of drug release at time t.  
The first order model was compared with the semi-empirical model 
introduced in 1983 by Peppas and co-workers to describe drug 
release from polymeric systems, commonly called the power law 
model [24].  
 
Mt / m = ktn 
  
where k is a constant incorporating the geometrical and structural 
characteristics of the macromolecular network system and the drug 
and n is the diffusional exponent, indicative of the transport 
mechanism. This equation is valid for the first 60% of the fractional 
release. For spheres where n = 0.43, the transport mechanism is 
dominated by Fickian diffusion, while anomalous non-Fickian 
transport is described by 0.43 < n < 1. When n = 1, zero-order 
release is obtained [25- 26]. The first order model and the power 
law model contain unknown parameters that were adjusted to the 
experimental data by a nonlinear least-squares algorithm with the 
software MATLAB. 
The criteria to choose the best model of release took into account 
the difference in the number of parameters between the first order 
model and the power law model and were based on the adjusted 
coefficient of determination [27]. 
 
R2adjusted = 1 – (ndp-1) / (ndp-p)=(1-R2) 
  
where ndp is the number of dissolution data points and p is the 
number of parameters in the model. The adjusted coefficient of 
determination is sensitive to the number of parameters in each 
model. The model that fits best will be represented by the highest 
adjusted coefficient of determination. 
Bacterial strain and growth conditions 
The E. coli K88 strain was donated by Dr. Carlos Eslava from the 
culture collection of Universidad Nacional Autonoma de Mexico 
and maintained as frozen stocks. Overnight cultures were grown in 
nutritive broth on a shaker at 37 ºC. The bacterial suspensions 
were adjusted to 0.5 units of optical density at 600 nm (108 
CFUmL−1) before use.  
In vitro antimicrobial activity 
GAM suspensions were stirred constantly and serially diluted (from 
0.1 mg/ml to 0.0015 µg/ml) in sterile nutritive broth and inoculated 
with 10 µL of E. coli K88 suspension (10 8 CFUml−1). Bacterial 
cultures were incubated at 37ºC for 24 h, and the minimal inhibitory 
concentration (MIC) was determined as the lowest concentration 
without visible growth. MIC was confirmed with subcultures in 
trypticase soy agar plates.  
Sustained in vitro antibacterial activity 
Antibacterial activity was determined as described by Egbaria et 
al.[28] and Wang et al. [29] with modifications. GAM (1 mg/mL) 
was suspended in nutrient broth (as release medium) with constant 
shaking at 37ºC. The media was removed every hour as follows: 
suspensions of microspheres were centrifuged, the supernatant 
was placed in sterile vials and the pellet was resuspended in new 
sterile nutrient broth. The process was repeated every hour until 12 
samples were collected. All recovered supernatants (nutrient 
broth/gentamicin-released) were inoculated with 10 µL of E. coli 
K88 suspension (108 CFUml−1) and incubated as described 
previously. 
Results and Discussion 
Microsphere characteristics 
GAM were prepared using the strategy of emulsion polymerization 
chemistry [16]. Glutaraldehyde-saturated toluene (GST) was used 
to promote polymerization on the surface of the GAM [16].  The 
G1, G2 and G3 treatments included glutaraldehyde concentrations 
of 4.2, 8.4 and 12.6 mg/g, respectively. The G1, G2, and G3 
treatments presented free spherical particles, as determined by 
SEM studies (Figure 1).  A tendency to form indentations with 
increasing amounts of GST was observed (Figure 1D). 
Indentations could be attributed to collisions or interactions 
between microspheres during synthesis when glutaraldehyde 
saturated with toluene was added one hour after starting emulsion, 
because at this time, the microspheres lost water and the 
surfactant was removed, followed by the interaction of the 
microspheres [30] Toluene works as a surfactant remover and also 
decreases the viscosity of the continuous phase. Smaller particles 
set faster and could collide with the surface of larger particles that 
harden more slowly.   
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The average particle size for each treatment varied from 10.5-12.3 
µm (Table 1). The particles were within the size range of those that 
are reported to remain in the intestinal lumen [14]. This retention is 
important to allow the release of antibiotics in areas typically 
infected by pathogens [31]. 
The yield for all treatments (G1, G2 and G3) was higher than 93%, 
and the encapsulation efficiency of gentamicin ranged from 87.5% 
to 97.3% (Table 1). However, the release efficiency of gentamicin 
appeared to be inversely affected by the amount of glutaraldehyde 
used for cross-linking the microspheres (Table 1). These results 
could be ascribed to glutaraldehyde cross-linking both albumin and 
gentamicin amino groups [32]. 
Gentamicin quantitation 
GAM were studied using infrared analysis to detect and quantify 
gentamicin in albumin microspheres. FT-IR is a common technique 
used to identify drugs; however, it is not widely used for 
quantification purposes. As expected, gentamicin and albumin 
showed different infrared spectra: for gentamicin, major 
absorbance peaks were at 619 and 1100-1400 cm-1, while for the 
albumin amide group, absorption occurred at 1651-1653 and 1574-
1548 cm-1. The GAMs’ spectra showed both albumin and 
gentamicin signals (Figure 2) that allowed for their rapid 
identification. To quantify gentamicin, a standard calibration curve 
was prepared; using the equation y= 0.0468x + 0.2552, the 
coefficient of determination obtained (R2) was 0.995. The G1, G2 
and G3 treatments presented gentamicin encapsulation efficiencies 
of 97.3±2, 92.2±2 and 87±0 (%), respectively (Table 1). There was 
a decrease of gentamicin content with increasing concentrations of 
cross-linking agent. This behavior is in agreement with reports 
demonstrating that the entrapment of drugs decreases with higher 
cross-link density due to microsphere pore volume reduction [33]. 
In vitro release studies 
Gentamicin release was measured using a dynamic dialysis 
system. In general, we found that gentamicin is released in a 
onestep profile, as shown in Figure 3. During the first four hours, 
69%, 72% and 92% of the gentamicin was released from G1, G2, 
and G3, respectively (Figure 3A). It is important to note that during 
diarrhea in pigs, intestinal transit from food intake to gastric 
emptying may take from 3 to 4 h [34]. Because of this, it is critical 
that therapeutic microspheres release antibiotic during the first four 
to six hours to counteract the colibacillosis present from the 
jejunum to the rectum. 
In these studies, the antibiotic liberation behavior was not affected 
by the amount of glutaraldehyde used. However, the amount of 
gentamicin released (release efficiency) was inversely proportional 
to the amount of glutaraldehyde present, as described previously. 
Similar antibiotic behavior was reported for vancomycin released 
from albumin microspheres [35]. 
Under acidic conditions (pH 2 and 4), the release of gentamicin 
was faster than at pH 6 (Figure 3B). Most of the gentamicin was 
released from the albumin microspheres (G1, G2 and G3 
formulations) during the first hour, probably because gentamicin is 
highly soluble at acidic pH, which allows for a rapid diffusion from 
the microspheres to the medium. This result is not convenient for 
an intestinal carrier system, which should be able to retain a drug 
in the acidic pH of the stomach environment. However, the problem 
could be solved by encapsulating the microspheres in gelatin 
capsules [36- 37]. Furthermore, as shown in figure 3C, the release 
of gentamicin from G2 was not affected by protease treatment. 
The release of gentamicin from GAM at pH 7.2 was analyzed using 
a first order model and compared to the power law model. Figure 4 
A, B and C show the matching between the first order model and 
the power law model along with the experimental data for G1, G2 
and G3, respectively. In the first order model, we found that the 
initial burst constant increases as the degree of cross-linkage in the 
microparticles preparation increases. The diffusional exponent 
obtained from the power law model for the three release studies 
was below the value of 0.43 expected for Fickian release behavior 
in spherical geometries. This result could be attributed to particle 
size distribution affecting the release kinetics. In comparison to the 
release behavior from a monodisperse sample, the presence of a 
particle size distribution causes a substantial acceleration in 
transport at early times and a marked retardation in transport at 
longer times[25]. Comparison between the adjusted coefficients of 
determination from both models indicates that gentamicin release 
from GAM could be better described by a first order equation than 
by a power law model. The parameters of both release models and 
the fitting with gentamicin release from GAM at pH 7.2 are listed in 
Table 2. 
In vitro antimicrobial activity 
GAM antibacterial activity against E. coli K88 was tested using the 
broth dilution technique (Table 3). The MIC for the G1, G2 and G3 
formulations was 3.12, 6.25 and 6.25 μg/ml, respectively. The  
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Figure 1. Scanning electron micrograph of gentamicin albumin-microspheres. (A) G1; (B) G2; (C) G3 and (D) close up of G3 
 
 
 
 
Figure 2. FT-IR of BSA, gentamicin and gentamicin albumin-microspheres. 
 
 
 
Table 1. Parameters and characteristics of gentamicin albumin-microspheres. 
Formulation 
code 
Glutaraldehyde 
added (mg) 
Yield (%) Encapsulation 
efficiency (%)* 
Release 
Efficiency (%) 
Mean particle 
size (µm) 
G1 0.28 94 ± 4.0 
 
97.3 ± 2 93.3 ± 3.3 
 
10.5±0.4 
G2 0.56 97± 1.5 
 
92.2 ± 2 62.5 ± 5.0 
 
12.0±0.7 
G3 0.84 93 ± 4.1 
 
87.5 ± 0 43.6 ± 6.5 
 
12.3±0.6 
*Determined by FT-IR 
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Figure 3. In vitro release profile of gentamicin from microspheres. (A) G1, G2, G3 and gentamicin in PBS (pH 7.2). (B) G2 in 
glycine-HCL, acetate and phosphate saline buffer at pH 2, 4 and 6, respectively. (C) G2 in phosphate buffered saline (pH 7.4) 
with trypsin and chymotrypsin. 
 
 
Figure 4. Models and experimental data matching gentamicin release from microspheres. (A) G1, (B) G2, and (C) G3. The 
points represent the experimental data; the solid line represents the first order release model, and the dashed line represents 
the power law model 
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Table 2. Parameters of gentamicin release from albumin microspheres in PBS, pH 7.2. 
Model Parameter Description Unit 
Formulation 
G1 G2 G3 
Power law k Characteristics of the macromolecular 
network system and the drug 
h-1 0.3996 0.4713 0.5629 
 n Diffusional exponent - 0.3204 0.2624 0.2195 
 R2 Coefficient of determination - 0.915 0.950 0.882 
 ndp Number of dissolution data points - 7 7 7 
 R2adjusted Adjusted coefficient of determination - 0.898 0.940 0.858 
First order kb Burst constant h-1 0.2867 0.3592 0.5058 
 R2 Coefficient of determination - 0.989 0.988 0.994 
 ndp Number of dissolution data points - 7 7 7 
 R2adjusted Adjusted coefficient of determination - 0.989 0.988 0.994 
 
 
 
Table 3. Minimal inhibitory concentration (MIC) obtained for gentamicin albumin-microspheres. 
  
 MIC (µg/ml) 
Formulation GAM Estimated 
[gentamicin] in 
GAM 
G1 3.125 0.47 
G2 6.25 0.63 
G3 6.25 0.44 
 MIC of free gentamicin = 0.31 (µg/ml) 
 
 
 
 
actual content of gentamicin (expressed as released efficiency, 
Table 1) was estimated to be 0.47, 0.63 and 0.44 mg/ml for G1, G2 
and G3, respectively. These values are close to the MIC obtained 
for free gentamicin (0.31 μg/ml). Additionally, the MIC of 
gentamicin against E. coli K88 found in this experiment is similar to 
the one reported for E. coli ATCC 25922 (0.5 µg/ml) [38]. Also, our 
data indicate that the encapsulation process by W/O emulsion 
does not affect the antibacterial activity of gentamicin. In contrast, 
Haswani et al. [20] reported a decrease in the antimicrobial activity 
of gentamicin encapsulated in albumin microspheres produced by 
the spray-dried method. 
 
Sustained in vitro antibacterial activity 
The antibacterial activity of gentamicin encapsulated in 
microspheres (formulation G2) against E. coli K88 was determined 
every hour for 12 h (1 mg of GAM was used). The released 
gentamicin maintained its antibacterial activity during the entire 12 
h of the experiment. According to the release kinetics shown in 
figure 3A, the amount of gentamicin released from 1 mg of G2 at 
12 h remained in the released medium at an approximate 
concentration of 1.6 µg/ml. This amount of gentamicin was higher 
than the MIC of G2, as shown in Table 3. 
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Conclusions 
The aim of this work is to determine the future use of GAM for oral 
transportation of gentamicin as a specific treatment for swine 
colibacillosis. Gentamicin-loaded albumin microspheres were 
obtained by emulsion and cross-linked with glutaraldehyde. The 
use of this cross-linking agent did not modify the release profile but 
did decrease the release efficiency. Chymotrypsin and trypsin 
activity did not affect the GAM’s properties, but acidic conditions 
increased drug release. The release of gentamicin from GAM could 
be described by a first order equation. Gentamicin from the 
microspheres showed antibacterial activity against E. coli K88. 
These results suggest that microsphere-gentamicin is a potential 
drug carrier and could be used for therapy against E. coli K88 
infection.  
Abbreviations and nomenclature 
Gentamicin-albumin microspheres (GAM), water/oil (W/O), 
Escherichia coli K88 (E. coli K88), Bovine serum albumin (BSA), 
Phosphate buffered saline (PBS), Fourier Transform Infrared (FT-
IR), minimal inhibitory concentration (MIC), Glutaraldehyde-
saturated toluene (GST).  
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